Sign in

Kevin Oleskewicz

Vice President on the Investment Banking team at Alliance Global Partners

Kevin Oleskewicz is a Vice President on the Investment Banking team at Alliance Global Partners, specializing in the proposal, structuring, and execution of capital markets and M&A transactions for small to mid-cap companies. He has directly contributed to several billion dollars in transaction value, covering companies such as Coda Octopus Group and Acurx Pharmaceuticals, with a strong focus on the healthcare and technology sectors. With over nine years of experience in project management and business analytics, Oleskewicz began his career following his graduation from Trinity College and has held increasing levels of responsibility at Alliance Global Partners since joining. He holds FINRA Series 79 and 63 registrations, signifying his professional credentials as a licensed securities representative.

Kevin Oleskewicz's questions to Coda Octopus Group (CODA) leadership

Question · Q3 2025

Kevin Oleskewicz asked about the feedback received from trials of the newly launched Echoscope Type Nano Gen series and inquired about the adjustment in the DAVD-related revenue target from $4.5 million to $3.5-$4 million.

Answer

Blair Cunningham, President - Technology, highlighted the 'remarkable reduction in form factor, size, and weight' of the Nano Gen series, which excites customers for new integration opportunities. Annmarie Gayle, Chairman & CEO, added that the smaller size opens up applications like the DCEND diving suit, previously impossible. Regarding DAVD revenue, Annmarie Gayle clarified that the company expects to hit $4 million for the fiscal year, a significant increase from $1.2 million last year, expressing satisfaction with this progress.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts